RxDoctor Payments Data

Keith Swanson, MD

Internal Medicine · Port St Lucie, FLNPI 1508952862

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $4,500 of the $6,600 with a category attached, or 68.2%. Pfizer accounts for 85.4% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $5,719 and has fallen 97.1% since, to $165 in 2025. Among internal medicine clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,600in general payments, 2019–2025

Across 36 payments — averaging $183.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$6K
  • Tactile Systems Technology Inc$315
  • Organogenesis Inc.$188
  • Smith+Nephew$173
  • Next Science LLC$76
  • Johnson & Johnson$64
  • plus $146 from 4 others

What the payments were for

  • Speaking & faculty fees$4,50068%
  • Travel & lodging$1,05116%
  • Food & beverage$1,04916%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,600 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida →

Medicare billing

Part B allowed, 2024
$52,047
Medicare patients
368
Services billed
688

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban50$35,270
XareltoRivaroxaban16$11,672
Rosuvastatin Calcium12$173

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$5,639$35,27050 claims
Johnson & JohnsonXarelto$64$11,67216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Port St Lucie

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →